More positive safety results for NewLink/Merck Ebola vaccine
This article was originally published in Scrip
Yet another study has shown an experimental Ebola vaccine from NewLink Genetics and its partner Merck to be safe, with the product eliciting robust antibody responses in all 40 of the healthy adults who received it at Walter Reed Army Institute of Research in Silver Spring, Maryland and at the National Institutes of Health (NIH) in Bethesda, Maryland.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.